Tempus is at the forefront of integrating artificial intelligence with precision medicine, aiming to transform the healthcare industry. By harnessing the power of data and AI, Tempus provides a suite of innovative technologies designed to enhance patient care, accelerate scientific discovery, and support healthcare providers in making more informed treatment decisions.
One of the key offerings from Tempus is its AI-enabled clinical assistant, which helps identify and close gaps in care. This tool is part of a broader ecosystem that includes LENS, a platform for finding, accessing, and analyzing multimodal real-world data, and ALGOS, which connects algorithmic models to assays for additional insights.
Tempus's commitment to advancing healthcare is further demonstrated through its extensive research and development efforts. The company has developed a pan-cancer organoid platform for precision medicine, showcasing the genomic and transcriptome fidelity of tumor organoid cultures from over 1,000 patients. Additionally, Tempus has validated a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA, highlighting the value of combining liquid biopsies with standard tissue genotyping.
With partnerships connecting over 65% of all Academic Medical Centers in the US and more than 50% of oncologists, Tempus is deeply integrated into the healthcare ecosystem. The company also collaborates with over 200 biopharma companies and has amassed a vast repository of de-identified research records to power scientific discovery.
Tempus continues to innovate with the beta launch of olivia, an AI-enabled personal health concierge app for patients, and the receipt of U.S. FDA 510(k) clearance for its Tempus ECG-AF device, which uses AI to identify patients at increased risk of atrial fibrillation/flutter.
Through its comprehensive approach to AI-enabled precision medicine, Tempus is not just improving patient care today but is also shaping the future of healthcare.
